Oesophageal Cancer is an uncontrolled growth of abnormal cells which forms in the lining of the oesophagus.
Epithelial tumours of the oesophagus are responsible for the majority of oesophageal cancers. The majority of oesophageal cancers can be subdivided into two main histological subtypes:
- Adenocarcinomas (AC)
- Squamous cell carcinomas (SCC)
This report provides the current incident population for Oesophageal Cancer across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, India, China, Japan, Argentina, Brazil, Mexico, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Oesophageal Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
There are several features associated with the development and progression of oesophageal cancer, these include:
- Fistula formation to trachea, bronchi or mediastinum (can be either due to direct tumour progression or iatrogenic effects (e.g. radiation therapy))
- Oesophageal perforation
- Nausea or vomiting
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in global Oesophageal Cancer market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Oesophageal Cancer and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Oesophageal Cancers incident population.
- Identify sub-populations within Oesophageal Cancer which require treatment.
- Gain an understanding of the specific markets that have the largest number of Oesophageal Cancer patients.